KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Change in Receivables: 2020-2021

Historic Change in Receivables for Recursion Pharmaceuticals (RXRX) over the last 2 years, with Sep 2021 value amounting to -$16,000.

  • Recursion Pharmaceuticals' Change in Receivables fell 100.05% to -$16,000 in Q3 2021 from the same period last year, while for Sep 2021 it was -$30.2 million, marking a year-over-year change of. This contributed to the annual value of -$114,000 for FY2021, which is 2380.00% down from last year.
  • As of Q3 2021, Recursion Pharmaceuticals' Change in Receivables stood at -$16,000, which was down 23.08% from -$13,000 recorded in Q2 2021.
  • In the past 5 years, Recursion Pharmaceuticals' Change in Receivables ranged from a high of $30.2 million in Q3 2020 and a low of -$30.0 million during Q4 2020.
  • Moreover, its 2-year median value for Change in Receivables was -$60,000 (2020), whereas its average is -$15,571.
  • Within the past 5 years, the most significant YoY rise in Recursion Pharmaceuticals' Change in Receivables was 78.33% (2021), while the steepest drop was 100.05% (2021).
  • Recursion Pharmaceuticals' Change in Receivables (Quarterly) stood at -$30.0 million in 2020, then tumbled by 100.05% to -$16,000 in 2021.
  • Its Change in Receivables stands at -$16,000 for Q3 2021, versus -$13,000 for Q2 2021 and -$85,000 for Q1 2021.